Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-23T14:20:35.467Z Has data issue: false hasContentIssue false

18 - Bladder

Published online by Cambridge University Press:  23 December 2009

Stephen Williams
Affiliation:
Specialist Registrar, Clinical Oncology, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
Jim Barber
Affiliation:
Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
Louise Hanna
Affiliation:
Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Hospital, Cardiff
Get access

Summary

Introduction

Bladder cancer is an important cause of morbidity and mortality and has a high incidence rate in industrialised countries. Each year in the UK, around 10,000 people develop a bladder cancer, and nearly half of those affected will die from their disease. Bladder cancers have a wide range of biological behaviours, from superficial tumours, which can be treated by local resection, to highly aggressive and infiltrative tumours. The treatment of invasive disease has traditionally been radical radiotherapy that has been given in an effort to avoid cystectomy. Although radiotherapy is still an important part of radical and palliative treatment, evidence is emerging that combined treatment modalities may improve outcomes.

Types of bladder tumour

The types of bladder tumour that can occur are shown in Table 18.1.

Incidence and epidemiology

Bladder cancer is the fourth most common cancer in men (6% of cancer cases) and the eighth most common cancer in women (2.5% of cases). The incidence is 17 per 100,000 of the population (CRUK; www.cancerresearchuk.org/). Because of recurrences, the prevalence in men is second only to prostate cancer. Bladder cancer is more common in white people. There has been a steady rise in the occurrence of bladder tumours over the past 20 years (33% in the USA). The peak age of incidence is 69 to 71 years.

Anatomy

The shape and size of the bladder change depending on how much urine it contains.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Advanced Bladder Cancer Meta-analysis Collaboration. (2003). Neoadjuvant chemotherapy in invasive bladder cancer: a systemic review and meta-analysis. Lancet, 361, 1927–34.CrossRef
Advanced Bladder Cancer Meta-analysis Collaboration. (2005). Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur. Urol., 48, 189–99; discussion 199–201.CrossRef
Alonzi, R. and Hoskin, P. (2005). Novel therapies in bladder cancer. Clin. Oncol. (R. Coll. Radiol.), 17, 524–38.CrossRefGoogle ScholarPubMed
Coppin, C. M., Gospodarowicz, M. K., James, K.et al. (1996). Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J. Clin. Oncol., 14, 2901–7.CrossRefGoogle ScholarPubMed
Duchesne, G. M., Bolger, J. J., Griffiths, G. O.et al. (2000). A randomized trial of hypo-fractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of Medical Research Council trial BA09. Int. J. Radiat. Oncol. Biol. Phys., 47, 379–88.CrossRefGoogle Scholar
Grossman, H. B., Natale, R. B., Tangen, C. M.et al. (2003). Neoadjuvant chemotherapy plus cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med., 349, 859–66.CrossRefGoogle ScholarPubMed
Harland, S. J. and the United Kingdom National Cancer Research Institute Bladder Clinical Studies Group. (2005). A randomised trial of radical radiotherapy in pT1G3 NXM0 bladder cancer (Medical Research Council BS06). J. Clin. Oncol., 23, (16 Suppl. I), 4505.CrossRefGoogle Scholar
International Collaboration of Trialists. (1999). Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle invasive bladder cancer: a randomised controlled trial. Lancet, 354, 533–40.CrossRef
Logue, J. and McBain, C. A. (2005). Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery. Clin. Oncol. (R. Coll. Radiol.), 17, 508–13.CrossRefGoogle Scholar
McLaren, D. B. (2005). Neoadjuvant chemotherapy in transitional-cell carcinoma of the bladder. Clin. Oncol., 17, 503–7.CrossRefGoogle ScholarPubMed
Muren, L. P., Smaaland, R. and Dahl, O. (2004). Conformal radiotherapy of urinary bladder cancer. Radiother. Oncol., 73, 387–98.CrossRefGoogle ScholarPubMed
Parmar, M. K., Freedman, L. S., Hargreave, T. B.et al. (1989). Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer working party). J. Urol., 142, 284–8.CrossRefGoogle Scholar
Petrioli, R., Frediani, B., Manganelli, A.et al. (1996). Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer, 77, 344–51.3.0.CO;2-1>CrossRefGoogle ScholarPubMed
Shelley, M. D., Barber, J., Wilt, T.et al. (2004). A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: are these data relevant to modern practice?Clin. Oncol. (R. Coll. Radiol.), 16, 166–71.CrossRefGoogle ScholarPubMed
Shelley, M. D., Court, J. B., Kynaston, H.et al. (2003). Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst. Rev., (3), cluster of differentiation003231.CrossRefGoogle ScholarPubMed
Shelley, M. D., Kynaston, H., Court, J.et al. (2001). A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. B. J. U. Int., 88, 209–16.CrossRefGoogle ScholarPubMed
Shipley, W. U., Zietman, A. L., Kaufman, D. S.et al. (2005). Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates – the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin. Radiat. Oncol., 15, 36–41.CrossRefGoogle ScholarPubMed
Sternberg, C. N., Mulder, P. H., Schornagel, J. H.et al. (2001). Randomised phase III trial of high dose intensity methotrexate, vinblastine, doxorubicin and cisplatin (methotrexate, vinblastine, doxorubicin, cisplatin) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic methotrexate, vinblastine, doxorubicin, cisplatin in advanced urothelial tract tumours: European Organisation for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol., 19, 2638–46.CrossRefGoogle Scholar
Sylvester, R. J., Oosterlinck, W. and Meijden, A. P. (2004). A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol., 171 (6 Pt. 1), 2186–90.CrossRefGoogle ScholarPubMed
International Union Against Cancer. (2002). tumour nodes metastases Classification of Malignant Tumours, ed. Sobin, L. H. and Ch., Wittekind. New York: Wiley-Liss, pp. 199–202.Google Scholar
Maase, H., Hansen, S. W., Roberts, J. T.et al. (2000). Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large randomised multinational multicentre phase III study. J. Clin. Oncol., 18, 3068–77.CrossRefGoogle ScholarPubMed
Winquist, E., Kirchner, T. S., Segal, R.et al. (2004). Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systemic review and meta-analysis. J. Urol., 171 (2 Pt. 1), 561–9.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Bladder
    • By Stephen Williams, Specialist Registrar, Clinical Oncology, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, Jim Barber, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.019
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Bladder
    • By Stephen Williams, Specialist Registrar, Clinical Oncology, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, Jim Barber, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.019
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Bladder
    • By Stephen Williams, Specialist Registrar, Clinical Oncology, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, Jim Barber, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.019
Available formats
×